High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.

In a series of three homologous and eight heterologous challenge experiments, it was shown that high potency vaccines against foot-and-mouth disease (FMD) serotype A can induce protection even against heterologous challenge infection with viruses that give low r-values with the vaccine strains. The challenge virus specific neutralizing antibody response on the day of challenge (21 days post vaccination) generally correlated with protection.